(PharmaNewsWire.Com, July 26, 2017 ) Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5-Pipeline Review H2 2017 outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia. The molecules developed by companies in Phase II Preclinical and Discovery stages are 3 9 and 1 respectively. Similarly the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules respectively. Report covers products from therapy areas Oncology and Immunology which include indications Prostate Cancer Pancreatic Cancer Bladder Cancer Melanoma Autoimmune Disorders Bone Metastasis Colorectal Cancer Breast Cancer Colon Carcinoma Glioblastoma Multiforme (GBM) Head And Neck Cancer Kidney Cancer (Renal Cell Cancer) Lymphoma Malignant Mesothelioma Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Metastatic Lung Cancer Multiple Myeloma (Kahler Disease) Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Non-Small Cell Lung Cancer Ovarian Cancer and Solid Tumor.
Furthermore this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities - The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects - The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles Biomics Biotechnologies Co Ltd Bioneer Corp Boehringer Ingelheim GmbH MimiVax LLC Optimum Therapeutics LLC Polyplus-Transfection SA Vaxeal Holding SA
List of Tables Number of Products under Development by Stage of Development H2 2017 Number of Products under Development by Therapy Areas H2 2017 Number of Products under Development by Indications H2 2017 Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Number of Products under Investigation by Universities/Institutes H2 2017 Products under Investigation by Universities/Institutes H2 2017 Number of Products by Stage and Mechanism of Actions H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Pipeline by Biomics Biotechnologies Co Ltd H2 2017 Pipeline by Bioneer Corp H2 2017 Pipeline by Boehringer Ingelheim GmbH H2 2017 Pipeline by MimiVax LLC H2 2017 Pipeline by Optimum Therapeutics LLC H2 2017 Pipeline by Polyplus-Transfection SA H2 2017 Pipeline by Vaxeal Holding SA H2 2017 Dormant Products H2 2017 Dormant Products H2 2017 (Contd..1) H2 2017 Discontinued Products H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
